TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Function improvement (Quick DASH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of treatment for scoliosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of DES development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Rate of disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Severity of postprandial epigastric discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Severity of postprandial fullness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Duration of absolute neutrophil count <500/mcL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of episodes of febrile neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Number of documented infections
Endpoint domain: Adverse events/effects
Primary endpoint: Metaphyseal index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of iron deficiency (ID)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean MCAv
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Response to esomeprazole therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Top-quality embryos/retrieved oocytes ratio (TQE/RO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MFIQ score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2 h postprandial plasma glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HAMD17 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAMD17 remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of sex
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Receptivity and initiation of sexual activity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: reductions in daily stress
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: improvements in satisfaction with body function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: changes in VO2max
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma FFA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean time for IOL implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: nocturnal wakefulness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wexner incontinence scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean PIPP score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median duration of crying
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left ventricular end diastolic diameter (LVEDD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: suppression of HBV-DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBeAg loss rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to positioning venous access
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Catheter failure rate
Endpoint domain: Adverse events/effects
Primary endpoint: PEDro total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Probing pocket depths
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implant restoration failure
Endpoint domain: Adverse events/effects
Primary endpoint: Skin thickness differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Subjective assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: composite CVD endpoint
Endpoint domain: Mortality/survival
Primary endpoint: Living ability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: DeltaCD62p
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: DeltaPAC‐1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of major adverse cardiac and cerebral events
Endpoint domain: Adverse events/effects
Primary endpoint: NRS‐11 reduction >= 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ODI reduction >= 30%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GPES >= 6
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Effective chest compressions duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of severity of gastroparetic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pharmacotherapy initiation and adjustment rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of diabetes, depression, and heart disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood pressure monitoring frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma propofol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BSR values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: betaTG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Postoperative mean visual analogue scale (VAS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume measurements at the level of pyriform sinus (VOL2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative mean MCA1 (minimal cross‐sectional area at the level of the nasal valve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NAFLD development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Angina severity (CCS score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thallium SPECT summed stress score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HbA(1c) ≤ 53 mmol/mol (7.0%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in I-QOL scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: elbow and shoulder joint movement range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: elbow and shoulder interjoint coordination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative conjunctival inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conjunctival recurrence of pterygium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Decreased mortality at day 70
Endpoint domain: Mortality/survival
Primary endpoint: Increased study composite endpoint success at days 42 and 70
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for polymer instrument without LA
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain experienced during treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of DWI-MRE for diagnosing bowel inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: operative wound complications
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of white spot lesions (WSLs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of BG measurements within target
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean BG concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Leg volume increase from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with evidence of oedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of leg swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: successful intervention development
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Time to primary endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: TDP sessions in the first week
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Practice diversity achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Present Pain Intensity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eradication rate of H pylori
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Homocysteine lowering
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: skin mark length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of visible holes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disappearance times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bile leak rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily output of biliary fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of alanine aminotransferase, aspartate aminotransferase and gamma glutamyl transpeptidase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of biliary sludge and casts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypersalivation reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preventing smoking relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lateral gait instability (frequency of lateral line stepping-over)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: YBOCS scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycemic control (HbA1c decline)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean serum 25OHD levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of metabolic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesic consumption of tramadol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Behavior ratings improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Side effects (pain and edema)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in serum vitamin C concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of burning/stinging
Endpoint domain: Adverse events/effects
Primary endpoint: Mean AMS improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional disability scale improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: vomiting after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for rescue antiemetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-year cardiovascular mortality
Endpoint domain: Mortality/survival
Primary endpoint: overall mood disturbance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for future abortion method
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Time to finalize procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma removal efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive rate of serum ANCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of coronary artery lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean 11-h serum glucose area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean fasting C-peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: degree of itching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical symptoms scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lichenoid change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of responders to vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Consumption of analgesics
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Lowering of very-low-density lipoprotein cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Physical activity opportunity per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shoulder‐tip pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain intensity ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of serious disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Inflammatory biomarkers (IL-6, MMP-9, P-Selectin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: phosphocreatine/adenosine triphosphate ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Risk of TMPRSS2:ETS-positive prostate cancer
Endpoint domain: Mortality/survival
Primary endpoint: Risk of TMPRSS2:ETS-negative prostate cancer
Endpoint domain: Mortality/survival
Primary endpoint: Oxygen dependency status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Breast feeding success at term
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematological parameters (Hb, MCV, MCH, MCHC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: NEI VFQ-25 composite scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Final AMI size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: overall survival time
Endpoint domain: Mortality/survival
Primary endpoint: Cardio-respiratory endurance test achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscular fitness test achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flexibility test achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of tooth sensitivity
Endpoint domain: Adverse events/effects
Primary endpoint: Peak Inspiratory Flow (PIF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: G. lamblia incidence
Endpoint domain: Adverse events/effects
Primary endpoint: A. lumbricoides incidence
Endpoint domain: Adverse events/effects
Primary endpoint: E. histolytica-associated diarrheal episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Change in PEF after salbutamol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Risk of AR exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of days taking rescue medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of needle passes required
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Opioid withdrawal symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Flexion withdrawal reflex threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate at day 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median duration of effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in prolapse scale of the PFDI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in urinary scale of the PFDI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: good functional outcome
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: recurrence risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diameter of right ICA-C6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: diameter of right OA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: length of left ICA-C6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Limb sensory function score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Superficial sensibility score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortical sensibility score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: late infections requiring hospitalizations
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in isopter area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distant recurrence rate at 9 years
Endpoint domain: Mortality/survival
Primary endpoint: Mean pupil size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-oriented composite endpoint (POCE)
Endpoint domain: Mortality/survival
Primary endpoint: immune response to Gram-negative and Gram-positive antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: incidence of tremor
Endpoint domain: Adverse events/effects
Primary endpoint: DVT rate
Endpoint domain: Adverse events/effects
Primary endpoint: PTE rate
Endpoint domain: Adverse events/effects
Primary endpoint: MSIS‐29 PHYS score improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: MSIS‐29 PSYCH score improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: EQ‐5D health utility index improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Colony-forming units of S mutans and S sobrinus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cumulative risk of having at least 1 false-positive screening test
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative risk of undergoing an invasive diagnostic procedure prompted by a false-positive test
Endpoint domain: Adverse events/effects
Primary endpoint: Global response to therapy
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: requirement for Magill forceps
Endpoint domain: Adverse events/effects
Primary endpoint: mean time for intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Guideline-concordant pharmacological treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to 6-segment maximum LV radial strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality of Care (QOC) improvement
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: bond failure rates
Endpoint domain: Mortality/survival
Primary endpoint: survival rate of teeth
Endpoint domain: Mortality/survival
Primary endpoint: mean corneal astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 0.5 MTF value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: partial response to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: component migration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Biliary cholesterol % molar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Megalin expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of CXRs with new findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of CXRs with new findings that resulted in interventions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody titres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes